Efficacy and tolerability of levocabastine and azelastine nasal sprays for the treatment of allergic rhinitis

Mediators of Inflammation

Volumn 4, Issue 7, 1995, Pages S11-S15

  Mösges, Ralph ^a   Spaeth, Joachim ^a   Klimek, Ludger ^b  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Allergic rhinitis; Azelastine; Levocabastine; Topical antihistamines

Indexed keywords

AZELASTINE; LEVOCABASTINE; NOSE SPRAY;

ADOLESCENT; ADULT; AGED; ALLERGIC RHINITIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DRUG EFFICACY; DRUG TOLERANCE; DYSPNEA; FEMALE; HUMAN; INTRANASAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SORE THROAT;

NEPTUNIA;

EID: 0029020884     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/S0962935195000780     Document Type: Article

References (12)

1. Awouters F, Niemegers C, Janssen T, et al. Levocabastine: pharmacological profile of a highly effective inhibitor of allergic reactions. Agents Actions 1992; 35: 12.
2. r antihistamine well-suited for topical application. In: Mygind N, Naclerio RM, eds. Rhinoconjunctivitis: New Perspectives in Topical Treatment of Seasonal Allergic Rhinitis. Proceedings of the Xlllth International Congress of Allergology and Clinical Immunology. Gottingen: Hogrefe and Huber, 1989; 27–34.
3. Megens AAHP, Vermeire J, Awouters FHL. Protection from compound 48/80-induced shock in rats: comparison of nine recent antihistamines with levocabastine. Life Science Advances. Pharmacology 1995; in press.
4. Sohoel P, Freng BA, Kramer J, et al. Topical levocabastine compared with oral terfenadine for the treatment of seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 1993; 92: 73–81.
5. Bahmer FA, Ruprecht KW. Safety and efficacy of topical levocabastine compared with oral terfenadine. Ann Allergy 1994; 72: 429–434.
6. The Livostin Study Group. A comparison of topical levocabastine and oral terfenadine in the treatment of allergic rhinoconjunctivitis. Allergy 1993; 48: 519–524.
7. The Swedish GP Allergy Team. Topical levocabastine compared with oral loratadine for the treatment of seasonal allergic rhinoconjunctivitis. Allergy 1994; 49: 611–615.
8. McTavish D, Sorkin EM. Azelastine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential. Drugs 1989; 38: 778–800.
9. Janssens MM-L, Howarth PH. The antihistamines of the nineties. Clin Rev Allergy 1993; 11: 111–153.
10. Mösges R, Dostal M, et al. Ist bei der allergischen Rhinitis die Therapie mit Azelastin Nasenspray wirkungsäquivalent der Systemischen Therapie mit Loratadin-Tabletten? In: Mösges R, Schlöndorff G (eds). Topische Therapie der allergischen Rhinitis. Zülpich, Germany: Biermann Verlag, 1993.
11. Dechant KL, Goa KL. Levocabastine: a review of its pharmacological properties and therapeutic potential as a topical antihistamine in allergic rhinitis and conjunctivitis. Drugs 1991; 41: 202–224.
12. Thomas KE, Ollier S, Ferguson H, Davies RJ. The effect of intranasal azelastine, Rhinolast®, on nasal airways obstruction and sneezing following provocation testing with histamine and allergen. Clin Exp Allergy 1992; 22: 642–647.